GEN-1 Immunotherapy Holds Promise for Newly Diagnosed Advanced Ovarian Cancer Patients, Study Says

GEN-1 Immunotherapy Holds Promise for Newly Diagnosed Advanced Ovarian Cancer Patients, Study Says
Combining the DNA-based immunotherapy GEN-1 with neoadjuvant standard-of-care chemotherapy to treat newly-diagnosed advanced ovarian cancer patients who will undergo interval debulking surgery seems to be a promising therapeutic approach, according to data from the OVATION study. Data recently announced by Celsion Corporation showed promising efficacy signals in the first nine patients dosed, including 100% disease control rate,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *